Very long-chainn-3 fatty acids and human health: fact, fiction and the future
Author:
Top Cited Papers
- 17 October 2017
- journal article
- conference paper
- Published by Cambridge University Press (CUP) in Proceedings of the Nutrition Society
- Vol. 77 (1) , 52-72
Abstract
EPA and DHA appear to be the most importantn-3 fatty acids, but roles forn-3 docosapentaenoic acid are now also emerging. Intakes of EPA and DHA are usually low, typically below those recommended. Increased intakes result in higher concentrations of EPA and DHA in blood lipids, cells and tissues. Increased content of EPA and DHA modifies the structure of cell membranes and the function of membrane proteins. EPA and DHA modulate the production of lipid mediators and through effects on cell signalling can alter the patterns of gene expression. Through these mechanisms, EPA and DHA alter cell and tissue responsiveness in a way that often results in more optimal conditions for growth, development and maintenance of health. DHA has vital roles in brain and eye development and function. EPA and DHA have a wide range of physiological roles, which are linked to certain health or clinical benefits, particularly related to CVD, cancer, inflammation and neurocognitive function. The benefits of EPA and DHA are evident throughout the life course. Future research will include better identification of the determinants of variation of responses to increased intake of EPA and DHA; more in-depth dose–response studies of the effects of EPA and DHA; clearer identification of the specific roles of EPA, docosapentaenoic acid and DHA; testing strategies to enhance delivery ofn-3 fatty acids to the bloodstream; and exploration of sustainable alternatives to fish-derived very long-chainn-3 fatty acids.Keywords
This publication has 249 references indexed in Scilit:
- Dietaryω-3 Polyunsaturated Fatty Acid DHA: A Potential Adjuvant in the Treatment of CancerBioMed Research International, 2013
- Marine polyunsaturated fatty acids and cancer therapyBritish Journal of Cancer, 2013
- Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCTEuropean Journal of Clinical Nutrition, 2012
- Specialized pro-resolving lipid mediators in the inflammatory response: An updateBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2010
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- A Pilot Randomized Controlled Trial of Omega-3 Fatty Acids for Autism Spectrum DisorderJournal of Autism and Developmental Disorders, 2010
- Cardiovascular effects of marine omega-3 fatty acidsThe Lancet, 2010
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- ω-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD StudyArchives of Neurology, 2006